Dysesthesia (abnormal skin sensation, typically burning or tingling) in 20.9% of 12mg participants versus 0.7% on placebo is the most discussed retatrutide safety finding from Phase III TRIUMPH-4. It is the signal that did not appear in Phase II, scaled with dose and exposure duration, and will be the subject of regulatory scrutiny when Eli Lilly files the New Drug Application.
The rest of the safety profile follows the pattern of GLP-1 receptor agonists, amplified somewhat by dose. Gastrointestinal effects (nausea, vomiting, diarrhoea, constipation) dominate early treatment and mostly resolve over the titration period. Discontinuation rates run higher at 12mg than at 9mg, reflecting both the dysesthesia finding and the stronger GI profile at the top dose.
This article walks through the full adverse event profile from TRIUMPH-4, the mechanism theories for dysesthesia, class comparison data against semaglutide and tirzepatide, and the practical considerations that matter for clinicians tracking this compound ahead of approval.
How retatrutide affects the body
Retatrutide (LY3437943) is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. The GLP-1 and GIP components drive the familiar incretin effects: delayed gastric emptying, increased satiety, improved insulin sensitivity. The glucagon component raises resting energy expenditure and increases hepatic fat oxidation.
Each receptor pathway carries its own side effect profile. GLP-1 activity drives the gastrointestinal effects and the modest heart rate increase seen across the class. GIP activity is generally well-tolerated and adds efficacy without much of a safety cost. The glucagon component is the novel variable and the leading candidate for the dysesthesia signal, though the mechanism has not yet been confirmed in published work.
Retatrutide is administered subcutaneously once weekly. Half-life is approximately six days. The titration schedule used in TRIUMPH runs 2mg, 4mg, 6mg, then 9mg or 12mg, with each step typically held for four weeks. Side effect frequency is highest during titration and tapers during maintenance, which is the same pattern seen with semaglutide and tirzepatide. See the Retatrutide Dosage Guide for full titration detail.
What the research says: TRIUMPH-4 adverse event profile
TRIUMPH-4 enrolled adults with obesity (BMI 30+) and moderate-to-severe knee osteoarthritis. The trial ran 68 weeks with participants randomised across 9mg, 12mg, and placebo arms. Topline results were released in December 2025. The Phase II trial (Jastreboff et al., New England Journal of Medicine, 2023, PMID: 37366315) is the companion evidence base and did not show the dysesthesia signal, which is why Phase III gets attention here.
Gastrointestinal effects
The GI profile accounts for the majority of adverse events across all arms. Nausea is the most frequent, affecting roughly 50 to 60% of participants at 12mg during titration and dropping to lower levels during maintenance. Vomiting appeared in approximately 30% at 12mg, diarrhoea in 25 to 30%, and constipation in 20 to 25%. Most GI events were graded mild-to-moderate and resolved with slower titration or antiemetic support.
These numbers are consistent with the class. Semaglutide's STEP 1 trial reported nausea in 44% of participants, and tirzepatide's SURMOUNT-1 reported 33% at 15mg. Retatrutide's higher GI frequency at 12mg reflects the stronger overall receptor activation at the top dose, not a different safety profile.
The dysesthesia signal
Dysesthesia in 20.9% of 12mg participants and 8.8% of 9mg participants (versus 0.7% placebo) is the finding that makes retatrutide different from semaglutide and tirzepatide on safety. The signal did not appear in the Phase II trial, where the same doses were tested over 48 weeks in a smaller population. Phase III exposure was longer (68 weeks) and enrolled more participants, which likely explains why the effect became visible.
Participants described burning, tingling, prickling, or pins-and-needles sensations, most often in the extremities. Eli Lilly has reported cases as predominantly mild-to-moderate and reversible on dose reduction or discontinuation. No permanent nerve injury has been recorded in trial disclosures to date.
The mechanistic hypothesis points at the glucagon receptor. Neither semaglutide (GLP-1 only) nor tirzepatide (GLP-1 plus GIP) produces this signal, so the glucagon component is the most obvious novel variable. Glucagon receptor activation has effects on peripheral metabolism and may interact with small nerve fibres, though the pathway is not yet established in published research. Longer follow-up from the other TRIUMPH trials will clarify whether this is a dose-limiting issue or a manageable side effect.
Cardiovascular and metabolic findings
Heart rate increased by approximately 5 to 8 beats per minute at 12mg, consistent with the GLP-1 class effect. Systolic blood pressure dropped by 14.0 mmHg at 12mg in TRIUMPH-4, a secondary benefit rather than an adverse effect. Liver enzymes did not show clinically significant changes, which matters given the glucagon receptor component and its effects on hepatic metabolism.
Serious adverse events
Serious adverse event rates in TRIUMPH-4 were low and broadly comparable across the dose arms and placebo. No drug-related deaths have been reported in the program. Pancreatitis, gallbladder disease, and thyroid tumour signals (the class-wide concerns for GLP-1 agonists) appeared at rates consistent with or lower than semaglutide and tirzepatide in comparable trials.
Practical breakdown
Retatrutide is investigational and not available by prescription. This section describes what a clinical rollout would likely look like based on trial management, not a protocol for current use. Grey-market sourcing carries safety risks that go beyond the side effect profile described here: unverified purity, sterility, and dosing accuracy are the dominant concerns with any unapproved peptide.
Managing GI effects during titration is the first practical consideration. Slower dose escalation (holding each step for six weeks instead of four, for example) reduces nausea frequency at the cost of slower time-to-maintenance. This is already standard practice with semaglutide and tirzepatide and will likely carry over to retatrutide post-approval. Staying at 9mg rather than escalating to 12mg may also become a common choice: the efficacy gain (26.4% at 9mg versus 28.7% at 12mg) is modest compared with the rise in dysesthesia incidence (8.8% versus 20.9%).
For dysesthesia specifically, the trial management approach has been dose reduction or discontinuation. There is no validated pharmacological intervention for drug-induced dysesthesia of this type, and symptoms have resolved on stopping treatment in reported cases. Whether the signal attenuates over very long exposure (beyond the 68-week TRIUMPH-4 window) is an open question that the remaining trials will address.
For a complete view of efficacy alongside these safety numbers, see the Retatrutide Clinical Trial Results article.
Class comparison: retatrutide vs semaglutide vs tirzepatide
On safety, the three compounds sit close together on the gastrointestinal profile and diverge on the dysesthesia signal. The table below pulls the comparable Phase III data.
| Adverse Event | Retatrutide 12mg | Tirzepatide 15mg | Semaglutide 2.4mg |
|---|---|---|---|
| Nausea | ~55% | 33% | 44% |
| Vomiting | ~30% | 13% | 24% |
| Diarrhoea | ~28% | 22% | 30% |
| Constipation | ~22% | 17% | 24% |
| Dysesthesia | 20.9% | Not reported | Not reported |
| Heart rate | +5–8 bpm | +3–5 bpm | +3–5 bpm |
Retatrutide figures approximated from TRIUMPH-4 topline disclosures; tirzepatide from SURMOUNT-1; semaglutide from STEP 1. Cross-trial comparison is indicative, not statistical.
Two observations from this comparison. First, retatrutide's GI frequency at 12mg runs higher than tirzepatide and semaglutide at their top doses, but the difference is modest and explainable by stronger receptor activation. Second, dysesthesia is the only category where retatrutide has a qualitatively different profile from the other two compounds. On every other axis, the safety story is familiar class territory.
The commercial and regulatory implication: retatrutide's approval case rests on whether the efficacy gain (28.7% versus 22.5%) justifies the dysesthesia signal for the 12mg dose. The 9mg dose may end up being the more widely used option in practice, where the efficacy advantage over tirzepatide remains (26.4% versus 22.5%) and the dysesthesia rate is considerably lower. See Retatrutide vs Tirzepatide for the full head-to-head.
Frequently asked questions
What are the most common retatrutide side effects?
Gastrointestinal: nausea, vomiting, diarrhoea, and constipation are reported most frequently, mirroring the class profile of other GLP-1 agonists. Nausea affected roughly 50-60% of participants at the 12mg dose in TRIUMPH-4, mostly during titration. Dysesthesia (abnormal skin sensation) is the distinctive retatrutide finding, reported in 20.9% at 12mg versus 0.7% on placebo.
What is dysesthesia and how serious is it?
Dysesthesia is abnormal skin sensation, typically described as burning, tingling, prickling, or pins-and-needles feelings. It was reported in 20.9% of TRIUMPH-4 participants at the 12mg dose and 8.8% at 9mg. Eli Lilly has characterised cases as mostly mild-to-moderate and reversible on discontinuation. No cases of permanent nerve injury have appeared in trial disclosures so far, though longer follow-up is pending.
How do retatrutide side effects compare with semaglutide and tirzepatide?
The gastrointestinal profile is broadly similar across the class: nausea, vomiting, and constipation dominate, mostly during titration. Retatrutide adds the dysesthesia signal (not seen with semaglutide or tirzepatide) and a somewhat higher discontinuation rate at the top dose. Gallbladder complications, pancreatitis risk, and heart rate increases appear across the class at comparable rates.
Why does retatrutide cause dysesthesia when similar drugs do not?
The prevailing hypothesis is the glucagon receptor component, which semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP) lack. Glucagon receptor activation affects peripheral metabolism and may interact with small nerve fibres, though the mechanism is not yet confirmed. The signal did not appear in Phase II, where the trial was shorter and the population smaller, so duration of exposure likely matters.
What is the discontinuation rate in Phase III trials?
Trial-reported discontinuation rates at 12mg were higher than at 9mg, reflecting both the dysesthesia finding and the amplified GI profile at the top dose. Specific percentages vary across the TRIUMPH trials and have been reported as in the low double-digits for the 12mg arm. Full per-trial discontinuation data will appear in peer-reviewed publications following topline release.
Are there long-term safety concerns with retatrutide?
The longest retatrutide exposure data comes from the 68-week TRIUMPH-4 trial. Concerns that apply to the GLP-1 class (thyroid C-cell tumours seen in rodent studies, pancreatitis, gallbladder disease) carry over and will be monitored in post-approval surveillance. The cardiovascular outcomes trial (TRIUMPH-3) will generate multi-year safety data, but that readout is expected later in the program.
Can retatrutide cause hypoglycaemia?
Severe hypoglycaemia has not been a prominent signal in TRIUMPH trials in non-diabetic populations, consistent with the broader GLP-1 class. Risk increases when retatrutide is used alongside insulin or sulfonylureas in type 2 diabetes, which is why TRIUMPH-2 (the diabetes trial) monitors this specifically. Non-diabetic users should not expect clinically meaningful hypoglycaemia from retatrutide monotherapy.
What side effects should prompt stopping treatment?
Persistent severe abdominal pain (possible pancreatitis), signs of gallbladder disease (right upper quadrant pain, jaundice), severe or progressive dysesthesia, or signs of allergic reaction warrant immediate medical review. Mild-to-moderate GI effects during titration are expected and typically resolve within weeks. Any decision to continue or stop treatment should be made with the prescribing clinician once retatrutide is approved and available.
This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug. It has not been approved by the FDA, EMA, MHRA, or any other regulatory agency. Side effect data described here comes from clinical trials conducted under medical supervision. Individual response varies, and side effects not seen in trials may emerge with broader post-approval use. Consult a licensed healthcare provider before starting, stopping, or changing any medication. Peptide File reports on research and does not sell, prescribe, or recommend sources for any compound discussed.